Business Wire

Finsk sykehus blir det første i verden som tar i bruk Ascom Myco smarttelefoner

27.8.2015 09:13 | Business Wire

Del

Kuopio University Hospital (KUH) i Finland er først i verden til å ta i bruk Ascom Myco, en smarttelefon spesialdesignet for helsesektoren. KUH har innført Ascom Myco på neonatalavdelingen.

«Det er selvfølgelig fantastiske nyheter at KUH ble det første sykehuset i verden til å bruke Ascom Myco», sier Ari-Pekka Tenko, direktør for salg og markedsføring hos Ascom Finland. «Det er spesielt gledelig å se Ascom Myco brukt i et så krevende og viktig miljø som neonatalavdelingen.»

KUHs interesse for den unike Ascom Myco smarttelefonen kom av sykehusets innføring av en ny pleiemodell med «familierom». Her blir nyfødte stelt i private familierom, slik at foreldre kan overnatte sammen med barnet. Forskning tyder på at slike miljøer kan forbedre prognosen for nyfødte, og forkorte sykehusoppholdet.

«Den nye modellen lar mødrene bo sammen med barna sine. Mor og barn skilles aldri, heller ikke om en av dem blir syk», sier sykepleier Mila Hilden, prosjektleder på KHUs neonatalavdeling.

Den nye omsorgsmodellen øker responstiden ved alarmer. Med nyfødte spredt rundt på flere private rom, måtte sykepleierne gå lenger for å lese alarmer på en skjerm. «Å løse dette problemet var utfordrende», sier Juhani Kouri, prosjektleder hos KHU. «Vi kunne ikke ha et varslingssystem som hørtes over hele avdelingen fordi nyfødte er spesielt følsomme for lyder. Å forhindre slike forstyrrelser kan gi betydelige fordeler, ettersom det kan bidra til å unngå livslang sykdom for nyfødte. Vi trengte derfor en smartere måte å administrere alarmer og pasientanrop på i den nye omsorgsmodellen.»

Løsningen ble Ascom Myco smarttelefoner sammen med Ascom Unite Assign (programvare for tildeling av oppgaver til personalet), er nå koblet til sykehusets pasientovervåkingsutstyr og pasientsignalsystem. Dette bidrar til sikrere og mer effektiv pleie for mødre og nyfødte.

«Alle alarmer fra pasientovervåkingen sendes nå til den relevante sykepleierens Ascom Myco smarttelefon», sier Tenko. «Sykepleieren kan se alarmtypen, alarmens prioritet, og hvilken pasient det gjelder. Hvis sykepleieren ikke har mulighet til å svare, blir alarmen videresendt til reservesykepleier. Ascom Myco reduserer risikoen for at varslinger blir ignorert, fordi de ikke automatisk blir sendt til alle sykepleiere, men bare går til de som er ansvarlig for et bestemt barn.»

ASCOM WIRELESS SOLUTIONS

Ascom Wireless Solutions (www.ascom.com/ws) er en ledende leverandør av innovative kommunikasjonsløsninger som gir integrerte, intelligente arbeidsprosesser for segmenter som sykehus, eldreomsorg, og andre områder der virksomhetskritisk kommunikasjon er viktig. Ca. 100 000 systemer er installert på verdensbasis. Selskapet tilbyr et bredt utvalg profesjonelle telefoni- og meldingssystemer som skaper verdi for kundene ved å støtte og optimalisere deres virksomhetskritiske prosesser. Løsningene er basert på mobil-, VoWiFi-, IP-DECT-, pasientsignal- og personsøkerteknologi, som integreres på en smart måte i eksisterende virksomhetssystemer. Ascom Wireless Solutions ble etablert i 1955 og har hovedkontor i Göteborg. Selskapet har datterselskaper i 13 land, og 1200 ansatte over hele verden. Det er en del av Ascom Group, som er børsnotert i Sveits (ASCN:SIX).

Contact information

For mer informasjon, besøk www.ascom.com/ws eller kontakt:
Ascom Finland
Ari-Pekka Tenko
Director Sales & Marketing
Telefon: +358 40 50 09 904
E-post: ari-pekka.tenko@ascom.com
eller
For mer informasjon om KUH:
Mila Hilden
+358 40 480 8889
mila.hilden@kuh.fi
eller
Juhani Kouri
+358 44 717 5871
juhani.kouri@kuh.fi

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom